Drug intelligence / Profile preview

PSMA-venadaparib

Development stage
Preclinical
Lead developer
Technical University of Munich
Modality
Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration
Intravenous
01

Overview

PSMA-venadaparib (also known as PSMA-Vena-16) is a small molecule/peptide-drug conjugate (PDC) designed for the targeted treatment of prostate cancer. It consists of a prostate-specific membrane antigen (PSMA)-targeting ligand conjugated to the potent, experimental poly(ADP-ribose) polymerase (PARP) inhibitor venadaparib via a cleavable disulfide (dithiolinker) linker. This design allows for selective delivery of venadaparib to PSMA-expressing prostate cancer cells, where intracellular glutathione (GSH) cleaves the linker to release the active PARP inhibitor. This targeted approach aims to enhance therapeutic efficacy while reducing systemic toxicities associated with conventional PARP inhibitors. Additionally, the conjugate can be radiolabeled (e.g., with Gallium-68 or Lutetium-177) for theranostic applications, enabling PET/SPECT imaging and targeted radionuclide therapy. It is being preclinically developed by researchers at the Technical University of Munich (TUM).

Other names
[177Lu]Lu-PSMA-Vena-16[68Ga]Ga-PSMA-Vena-16PSMA-Vena-16PSMA-Vena16PSMA-Vena 16PSMA-venadaparib drug conjugate
02

Identity

Drug type
Radiopharmaceuticals
Modality
Peptide-Drug Conjugates
03

Pharmacology

04

Development

IndicationHighest phaseStatus
prostate cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Technical University of MunichLead developer
07

Competitive landscape

Drugs on the same target
195
Drugs in the lead indication
564

Lead indication: prostate cancer and precursor lesions

Most advanced in the lead indication

  1. 18F-PSMA-11Approved
  2. flotufolastat f 18Approved
  3. gallium ga-68 gozetotideApproved
  4. piflufolastat f 18Approved
  5. aminocaproic acidApproved

Beyond the preview

Go deeper on PSMA-venadaparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSMA-venadaparib.

Work on PSMA-venadaparib? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call